Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study

José L. Manzano, Juan Martin-Liberal, Luis A. Fernández-Morales, Gretel Benítez, Javier Medina Martínez, María Quindós, Almudena García-Castaño, Ovidio Fernández, Rocío V. Simo, Margarita Majem, Lorena Bellido, Pablo Ayala de Miguel, Begoña Campos, Enrique Espinosa, José A. Macías Cerrolaza, Irene Gil-Arnaiz, David Lorente, Alvaro Rodriguez-Lescure, Victor N. Perez, Rafael López Castro, María G. Gramaje, Teresa Puértolas, Juan F. Rodriguez Moreno, Laia Espasa Font, Guillermo Belaustegui Ferrández, Pablo Cerezuela-Fuentes

Open source

DOI
10.1097/cmr.0000000000000888
Published
2023-03-28
Container
Melanoma Research
Publisher
Ovid Technologies (Wolters Kluwer Health)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/cmr.0000000000000888,
  title = {Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study},
  author = {José L. Manzano and Juan Martin-Liberal and Luis A. Fernández-Morales and Gretel Benítez and Javier Medina Martínez and María Quindós and Almudena García-Castaño and Ovidio Fernández and Rocío V. Simo and Margarita Majem and Lorena Bellido and Pablo Ayala de Miguel and Begoña Campos and Enrique Espinosa and José A. Macías Cerrolaza and Irene Gil-Arnaiz and David Lorente and Alvaro Rodriguez-Lescure and Victor N. Perez and Rafael López Castro and María G. Gramaje and Teresa Puértolas and Juan F. Rodriguez Moreno and Laia Espasa Font and Guillermo Belaustegui Ferrández and Pablo Cerezuela-Fuentes},
  year = {2023},
  journal = {Melanoma Research},
  doi = {10.1097/cmr.0000000000000888},
  url = {https://doi.org/10.1097/cmr.0000000000000888}
}

RIS

TY  - JOUR
TI  - Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study
AU  - José L. Manzano
AU  - Juan Martin-Liberal
AU  - Luis A. Fernández-Morales
AU  - Gretel Benítez
AU  - Javier Medina Martínez
AU  - María Quindós
AU  - Almudena García-Castaño
AU  - Ovidio Fernández
AU  - Rocío V. Simo
AU  - Margarita Majem
AU  - Lorena Bellido
AU  - Pablo Ayala de Miguel
AU  - Begoña Campos
AU  - Enrique Espinosa
AU  - José A. Macías Cerrolaza
AU  - Irene Gil-Arnaiz
AU  - David Lorente
AU  - Alvaro Rodriguez-Lescure
AU  - Victor N. Perez
AU  - Rafael López Castro
AU  - María G. Gramaje
AU  - Teresa Puértolas
AU  - Juan F. Rodriguez Moreno
AU  - Laia Espasa Font
AU  - Guillermo Belaustegui Ferrández
AU  - Pablo Cerezuela-Fuentes
PY  - 2023
JO  - Melanoma Research
DO  - 10.1097/cmr.0000000000000888
UR  - https://doi.org/10.1097/cmr.0000000000000888
ER  - 

APA

Manzano, J. L., Martin-Liberal, J., Fernández-Morales, L. A., Benítez, G., Martínez, J. M., Quindós, M., García-Castaño, A., Fernández, O., Simo, R. V., Majem, M., Bellido, L., Miguel, P. A. D., Campos, B., Espinosa, E., Cerrolaza, J. A. M., Gil-Arnaiz, I., Lorente, D., Rodriguez-Lescure, A., Perez, V. N., Castro, R. L., Gramaje, M. G., Puértolas, T., Moreno, J. F. R., Font, L. E., Ferrández, G. B., & Cerezuela-Fuentes, P. (2023). Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study. Melanoma Research. https://doi.org/10.1097/cmr.0000000000000888

Source records